omalizumab (xolair) Report issue

Biologics mAb Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW
  • Now
Omalizumab, sold under the brand name Xolair, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), and immunoglobulin E-mediated food allergy.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$158.9365 - $317.8730

United States

$204.3700 - $1118.3300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

anti-ige | anti-ige antibodies | anti-igeid | ige025 | ige25 | olizumab | omalizumab | rg-3648 | rhumab-e25 | xolair

Organizations (160)

Research & Development (160)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (48)

Approved Indications (2)


 

Asthma

Urticaria

Experimental Indications - Clinical Trial Phases 1-4 (48)


 

Allergy and Immunology (Phase 3)

Anaphylaxis (Phase 2)

Angioedema (Phase 4)

Aspergillosis, Allergic Bronchopulmonary (Phase 4)

Aspirin (Phase 4)

Asthma ()

Autism Spectrum Disorder (Phase 1)

Bronchial Spasm (Phase 2)

Bronchitis (Phase 2/Phase 3)

Child (Phase 4)

Chronic Urticaria (Phase 4)

Colonic Neoplasms (Phase 1)

COVID-19 (Phase 2)

Cystic Fibrosis (Phase 4)

Cystitis, Interstitial (Phase 3)

Dermatitis, Atopic (Phase 4)

Drug Hypersensitivity (Phase 1)

Eosinophilic Esophagitis (Phase 1)

Esophagitis (Phase 2)

Food Hypersensitivity (Phase 4)

Gastroenteritis (Phase 2)

Healthy Volunteers (Phase 1)

Hypersensitivity (Phase 4)

Hypotension (Phase 2)

Immune System Diseases (Phase 1)

Immunotherapy (Phase 2)

Infertility, Female (Phase 2)

Job Syndrome (Phase 1)

Lung Diseases (Phase 4)

Lupus Erythematosus, Systemic (Phase 1)

Mastocytosis (Phase 2/Phase 3)

Milk Hypersensitivity (Phase 2)

Nasal Polyps (Phase 4)

Nephritis (Phase 2)

Omalizumab (Phase 2)

Peanut Hypersensitivity (Phase 3)

Pemphigoid, Bullous (Phase 4)

Pharmacokinetics (Phase 1)

Physiological Effects of Drugs (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 3)

Signs and Symptoms (Phase 2)

Sinusitis (Phase 4)

Sjogren's Syndrome (Phase 1)

Urticaria ()

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 182
  • # of Trial Organizations: 160

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue